← Eichor
Study identifier: NCT07243964 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

Condition: Lung Diseases  ·  Sponsor: Chang Chen

PhaseN/A
Planned participants244
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).

This description comes directly from the study's public registry record.

Talk to the study team

Junqi Wu  ·  +8615618977421  ·  wujunqi@tongji.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Pulmonary HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07243964